About Bionano Genomics
Bionano Genomics (NASDAQ:BNGO) specializes in offering tools and services based on its Saphyr system for the analysis of chromosomes, known as cytogenomics. This technology provides researchers and clinicians with a deeper understanding of genetics and the structure of the genome, aiding in the detection of diseases and disorders that conventional cytogenetics might miss. Focused on revolutionizing the way genomic research is conducted, Bionano aims to unlock critical genomic information with high-throughput and high-resolution capabilities. The company is dedicated to advancing the field of genomics, striving to make its cutting-edge technology an integral part of research and clinical diagnostics. By pushing the boundaries of genomic analysis, Bionano's objective is to contribute to the development of personalized medicine and improve healthcare outcomes.
Snapshot
Operations
Products and/or services of Bionano Genomics
- Saphyr System: A genome imaging tool for high-throughput chromosomal conformation capture, providing insights into structural variations and complex rearrangements.
- Preclinical Research Services: Offering genome analysis services, leveraging the Saphyr system for genetic disease research and drug development.
- Bionano Prep Kits: Consumables tailored for the Saphyr system, enabling efficient sample preparation for genome imaging.
- Data Analysis Services: Providing comprehensive genome data analysis, interpretation, and reporting services to accelerate research findings.
Bionano Genomics executive team
- Dr. Robert Erik Holmlin M.B.A., Ph.D.President, CEO, CFO & Director
- Mr. Mark OldakowskiChief Operating Officer
- Dr. Alka Chaubey FACMG, Ph.D.Chief Medical Officer
- Mr. Mark Adamchak CPAVP of Accounting & Controller
- Mr. Jonathan Dixon J.D.General Counsel & Secretary
- Ms. Donna PolizioGlobal Head of Market Access
- Mr. Cory KreeckGlobal Head of People Operations